Rita Medical to Present at the Pacific Growth Equities Life Sciences Growth Conference
Rita Medical to Present at the Pacific Growth Equities Life Sciences Growth Conference
June 9, 2006 at 12:00 AM EDT
FREMONT, Calif., June 9 /PRNewswire-FirstCall/ -- RITA Medical Systems, Inc. (Nasdaq: RITA), a publicly-traded medical device company focused solely on cancer therapies, today announced that it has been invited to present at the Pacific Growth Equities Life Sciences Growth Conference, which will take place at the InterContinental Mark Hopkins Hotel in San Francisco. The Company is scheduled to discuss its business strategy and historical financial performance on Monday, June 12, 2006 at 10:00 a.m. Pacific Time.
Attendance at the conference is by invitation only. RITA Medical will offer a live audio webcast of its presentation which may be accessed at the Company's website at www.ritamedical.com. An archived replay of the presentation will also be available approximately three hours following the live presentation and will also be available at www.ritamedical.com.
About RITA Medical Systems, Inc.
RITA Medical Systems develops, manufactures and markets innovative products for cancer patients including radiofrequency ablation (RFA) systems and embolization products for treating cancerous tumors as well as percutaneous vascular and spinal access systems. The Company's oncology product lines include implantable ports, some of which feature its proprietary Vortex® technology; tunneled central venous catheters; and safety infusion sets and peripherally inserted central catheters used primarily in cancer treatment protocols. The radiofrequency product line also includes the HABIB 4X resection device, which coagulates a "surgical resection plane" and is designed to facilitate a fast dissection in order to minimize blood loss and blood transfusion during surgery. The proprietary RITA RFA system uses radiofrequency energy to heat tissue to a high enough temperature to ablate it or cause cell death. In March 2000, RITA became the first RFA company to receive specific FDA clearance for unresectable liver lesions in addition to its previous general FDA clearance for the ablation of soft tissue. In October 2002, RITA again became the first company to receive specific FDA clearance, this time for the palliation of pain associated with metastatic lesions involving bone. The Company also distributes LC Bead embolic microspheres in the United States. The LC Bead microspheres are injected into selected vessels to block the blood flow feeding a tumor, causing it to shrink over time, and are often used in combination with radiofrequency ablation (RFA). The RITA Medical Systems website is at www.ritamedical.com.
SOURCE RITA Medical Systems, Inc. 06/09/2006
CONTACT: Investors, Doug Sherk, dsherk@evcgroup.com, or Jennifer Beugelmans, both at +1-415-896-6820, or Media, Steve DiMattia, +1-646-277-8706, or sdimattia@evcgroup.com, all of EVC Group for RITA Medical Systems, Inc.; Joseph DeVivo, President and CEO of RITA Medical Systems, Inc., +1-510-771-0400
Web site: http://www.ritamedical.com
(RITA)
Attendance at the conference is by invitation only. RITA Medical will offer a live audio webcast of its presentation which may be accessed at the Company's website at www.ritamedical.com. An archived replay of the presentation will also be available approximately three hours following the live presentation and will also be available at www.ritamedical.com.
About RITA Medical Systems, Inc.
RITA Medical Systems develops, manufactures and markets innovative products for cancer patients including radiofrequency ablation (RFA) systems and embolization products for treating cancerous tumors as well as percutaneous vascular and spinal access systems. The Company's oncology product lines include implantable ports, some of which feature its proprietary Vortex® technology; tunneled central venous catheters; and safety infusion sets and peripherally inserted central catheters used primarily in cancer treatment protocols. The radiofrequency product line also includes the HABIB 4X resection device, which coagulates a "surgical resection plane" and is designed to facilitate a fast dissection in order to minimize blood loss and blood transfusion during surgery. The proprietary RITA RFA system uses radiofrequency energy to heat tissue to a high enough temperature to ablate it or cause cell death. In March 2000, RITA became the first RFA company to receive specific FDA clearance for unresectable liver lesions in addition to its previous general FDA clearance for the ablation of soft tissue. In October 2002, RITA again became the first company to receive specific FDA clearance, this time for the palliation of pain associated with metastatic lesions involving bone. The Company also distributes LC Bead embolic microspheres in the United States. The LC Bead microspheres are injected into selected vessels to block the blood flow feeding a tumor, causing it to shrink over time, and are often used in combination with radiofrequency ablation (RFA). The RITA Medical Systems website is at www.ritamedical.com.
SOURCE RITA Medical Systems, Inc. 06/09/2006
CONTACT: Investors, Doug Sherk, dsherk@evcgroup.com, or Jennifer Beugelmans, both at +1-415-896-6820, or Media, Steve DiMattia, +1-646-277-8706, or sdimattia@evcgroup.com, all of EVC Group for RITA Medical Systems, Inc.; Joseph DeVivo, President and CEO of RITA Medical Systems, Inc., +1-510-771-0400
Web site: http://www.ritamedical.com
(RITA)